TODAY : Monday, 21 April 2025
Code
KLBF
Title
PT. Kalbe Farma Tbk
Address
Head Office:
Address:Gedung KALBE
Jl. Let.Jend Suprapto Kav 4, Cempaka Putih - Jakarta Pusat 10510
Phone:(021) 4287 3888
Fax:(021) 4287 3680
E-mail:info@kalbe.co.id
Website:www.kalbe.co.id
Marketing Office:
Enseval Building
Jl. Let.Jend. Suprapto - Jakarta 10510
Phone:(021) 4287.3888
Fax:(021) 4287.3680
E-mail:info@kalbe.co.id
Website:www.kalbe.co.id
Manufacture:
Jl. Jend. A. Yani (Pulomas)
Jakarta Timur 13210
Phone:(021) 489 2808
Fax:(021) 489 3549; (021) 489 1502
E-mail:info@kalbe.co.id
Website:www.kalbe.co.id
Background

The Company is primarily engaged in the development, manufacturing and trading of pharmaceutical preparation including medicines and consumer health products.

Business cp product

The Company is primarily engaged in the development, manufacturing and trading of pharmaceutical preparation including medicines and consumer health products.

Subsidiary affiliation
SubsidiariesDomicileBusiness%
Pharmaceutical
PT Bintang ToedjoeJakartaPharmaceutical100
PT Hexpharm Jaya LaboratoriesJakartaPharmaceutical100
PT Saka Farma LaboratoriesJakartaPharmaceutical100
PT Finusolprima Farma Int.JakartaPharmaceutical100
PT Bifarma AdiluhungJakartaHealth screening service100
Innogene Kalbiotech Pte. Ltd.SingaporeAgent and representative for biotechnology products93.34
PT Dankos FarmaJakartaPharmaceutical100
PT Pharma Metric Labs.JakartaQuality Control Certification Service and81.64
Clinical Trial for Pharmaceutical and Consumer Health Products
PT KalGen DNAJakartaScreening Service, Supporting Diagnostic Test and Reagen Production60
PT Kalbio Global MedikaJakartaManufacturing of Biologic Products100
PT Kalbe Genexine BiologicsJakartaPharmaceutical60
PT Innolab Sains InternasionalJakartaHealth Screening Service60
PT global Onkolab FarmaJakartaPharmaceutical100
PT Kalbe Myanmar Company Ltd.MyanmarPharmaceutical100
Health Foods and Drinks
PT Sanghiang PerkasaJakartaHealth Foods100
PT Kalbe Morinaga IndonesiaJakartaHealth Foods70
PT Hale InternationalBogorHealth Drinks100
PT Kalbe Milko IndonesiaBogorHealth Foods51
PT global Vita NutritechJakartaPremix Industry100
Sale and Distribution
PT Enseval Putera Megatrading TbkJakartaDistribution of Pharmaceutical Products,91.8
Consumer Products, Medical Equipment,
Cosmetics and Other Trading Products
PT Tri Sapta JayaJakartaDistribution of Pharmaceutical Products and91.8
Medical Equipment
PT Millenia Dharma InsaniJakartaHealth Care Clinics91.8
PT Enseval Medika PrimaJakartaTrading of Medical and Laboratory Equipment and Supplies91.8
PT Global Chemindo MegatradingJakartaTrading of Raw Materials for Pharmaceutical91.8
Products
PT Global Karsa MedikaJakartaWholesale trading of pharmaceutical, medical equipment, foods and drinks91.8
PT Renalmed Tiara UtamaJakartaTrading of Consumable Products for90.65
Hemodialysis Therapy
Kalbe Vision Pte. Ltd.SingaporeDevelopment, Production, Marketing and100
Distribution of Opthalmic Products
Kalbe International Pte.Ltd.SingaporeWholesale of Pharmaceutical, Consumer Health and Nutrition Products100
Asiawide Kalbe Philippines, Inc.PhilippinesMarketing and Distribution of Energy Drinks in a Ready-to-Drink Format50
PT Karsa Lintas BuwanaJakartaAdvertising100
Kalbe Malaysia Sdn. Bhd.MalaysiaWholesale of Pharmaceutical and Medical100
Products
PT Medika Renal CitraprimaJakartaHemodialysis Clinic, Trading of Consumable91.8
Products for Hemodialysis Therapy
PT Medika Komunika TeknologiJakartaE-commerce, web portal and online media services50
PT Cakra Radha MustikaJakartaDigital marketing services100
PT Karya Hasta DinamikaJakartaHome delivery service100
Kalbe Global Pte. LtdSingaporeHolding company100
Commissioners
President Commissioner: Bernadette Ruth Irawati Setiady
Commissioner: Santoso Oen
Commissioner: Ronny Hadiana
Commissioner: Budi Dharma Wreksoatmodjo
Independent Commissioner: Rhenald Kasali
Independent Commissioner: Lilis Halim
Per 30 Sep 2023
Directors
President Director: Vidjongtius
Director: Bernadus Karmin Winata
Director: Sie Djohan
Director: Mulialie
Director: Jos Iwan Atmadjaja
Director: Kartika Setiabudy
Per 30 Sep 2023
Underwriter
PT. Merincorp
PT. Niaga Securities
Share registrar
PT. Adimitra Transferindo
Share holders
ShareholdersShares%
PT. Gira Sole Prima482450948510.29
PT. Santa Seha Sanadi471812194010.07
PT. Diptanala Bahana44548070409.5
PT. Lucasta Murni Cemerlang44398954409.47
PT. Ladang Ira Panen490318574010.46
PT. Bina Artha Charisma38416390408.2
B.R. Irawati Setiady215880000.05
Ronny Hadiana910710070.19
Mulialie2500450
Public (< 5%)1896057367340.69
Treasury Stock6194807001.32
As of Sep 30, 2022
History stocks

Type of ListingDatePrice## of SharesTotal Listed Shares

IPO @ Rp. 7,80030-Jul-199110001000000050000000

1:1 Bonus Issue30-Oct-1992100050000000100000000

8:100 Rights @ Rp. 8,53030-Apr-199310008000000108000000

3:10 Stock Div.16-Jun-1994100032400000140400000

7;10 Bonus Issue30-Jun-1994100075600000216000000

Stock Split2-Oct-1996500216000000432000000

Stock Split24-Sep-199910017280000002160000000

Bonus Issue06-Dec-200010019008000004060800000

Stock Split02-Jan-20045040608000008121600000

Conversion DNKS (PT. Dankos)21-Dec-2005506836419068805241906

Conversion PT. Enseval21-Dec-200550135077251610156014422

Stock Split 1 : 508-Oct-2012104062405768850780072110

Decrease in Issued and Fully Paid Shares13-Dec-201310-390495000046875122110

Other infos

International Activities

Sales mostly generated by OTC (Over the Counter) products such as WOODS, MIXAGRIP, PROCOLD, MEDIK 55, PROMAG, ZAIKI, CORINZHA and MILNA.

Per 21 December 2005, Merger PT. Dankos Laboratories Tbk (DNKS) & PT. Enseval

Created date
2023-11-02 14:54:54
Revised date
2023-11-02 14:54:54
Finance
 
PT. Kalbe Farma Tbk
 
Financial Statetment Date
Fiscal Year Ends
Months Covered in Income St
 
Summary Covered in Income St
Cash and Cash Equivalents
Receivables
Inventories
Current Assets
Fixed Assets
Other Assets
Non Current Assets
Total Assets
Current Liabilities
Longterm Liabilities
Total Liabilities
Authorized
Paid-up Capital
Par Value
Paid-up Capital Shares
Retained Earnings
Total Equity
Minority Interest
 
Summary of Income Statement
Total Sales
Cost of Good Sold
Gross Profit
Operating Profit
Other Income
Earning Before Tax
Tax
Net Income
Close Price
 
Per Share Data (Rp)
Eps (annualized)
Book Value
 
Financial Ratios
Debt Equity Ratio (X)
Roa(%)
Roe(%)
Npm(%)
Opm(%)
Gross Profit Margin (%)
Total Assets Turnover
 
Cash Flow
CF from Operation Activities
CF from Investing Activities
CF from Financing Activities
Net Increase in Cash & Cash Equivalent
Cash & Cash Equivalent at Beginning of the Year
Cash & Cash Equivalent at The End of the Year
2020-12-31 2020-09-30 2020-06-30 2020-03-31
Dec Dec Dec Dec
12 9 6 3
 
 
5,207,929,420.50 4,400,008,242.09 4,008,793,496.59 3,921,022,446.87
3,594,926,677.69 3,607,724,998.79 3,617,297,231.30 3,961,641,104.33
3,599,745,931.24 4,161,626,148.60 4,186,266,611.24 3,682,863,653.61
13,075,331,880.72 12,887,113,859.82 12,607,408,568.43 12,672,173,477.94
8,157,762,093.28 8,188,466,673.24 8,128,025,655.62 7,929,049,361.04
274,801,064.58 258,215,195.53 291,873,441.48 437,001,280.97
9,488,968,436.66 9,563,424,709.89 9,483,693,955.81 9,459,980,821.59
22,564,300,317.37 22,450,538,569.71 22,091,102,524.24 22,132,154,299.53
3,176,726,211.67 3,362,011,464.59 3,858,586,634.69 3,848,869,597.82
1,111,491,961.62 1,185,930,578.71 1,051,845,055.82 1,026,952,412.93
4,288,218,173.29 4,547,942,043.29 4,910,431,690.51 4,875,822,010.75
85,000,000.00 85,000,000.00 85,000,000.00 85,000,000.00
468,751,221.10 468,751,221.10 468,751,221.10 468,751,221.10
10.00 10.00 10.00 10.00
46,875,122.11 46,875,122.11 46,875,122.11 46,875,122.11
16,875,670,700.52 16,451,065,267.28 15,811,188,249.45 15,803,749,090.72
17,405,532,929.39 17,055,114,152.16 16,341,562,083.06 16,437,431,134.69
870,549,214.68 847,482,374.25 839,108,750.68 818,901,154.09
 
 
23,112,654,991.22 17,095,837,856.58 11,604,512,137.02 5,795,613,126.65
12,866,332,497.45 9,324,489,927.59 6,351,862,987.84 3,178,269,295.01
10,246,322,493.77 7,771,347,928.99 5,252,649,149.18 2,617,343,831.64
3,829,009,875.61 2,742,054,470.13 1,904,889,177.26 934,484,840.74
-201,377,300.87 -54,284,523.51 -95,966,531.93 -46,922,863.23
3,627,632,574.74 2,687,769,946.62 1,808,922,645.33 887,561,977.51
828,010,058.93 615,545,810.28 400,741,562.59 210,533,400.85
2,733,259,864.59 2,027,403,698.69 1,387,526,680.87 669,269,022.35
1,480.00 1,550.00 1,460.00 1,200.00
 
 
58.31 57.67 59.20 57.11
371.32 363.84 348.62 350.66
 
 
0.25 0.27 0.30 0.30
12.11 12.04 12.56 12.10
15.70 15.85 16.98 16.29
11.83 11.86 11.96 11.55
16.57 16.04 16.42 16.12
44.33 45.46 45.26 45.16
1.02 0.76 0.53 0.26
 
 
4,221,549,815.09 2,523,258,517.18 1,536,767,131.54 721,339,445.76
-951,215,261.38 -755,347,238.41 -568,806,001.33 -342,015,311.85
-1,099,712,433.60 -510,115,533.72 -79,946,071.98 296,222,798.37
2,170,622,120.11 1,257,795,745.05 888,015,058.23 675,546,932.29
2,992,848,856.46 3,040,487,103.57 3,040,487,103.57 3,040,487,103.57
5,207,929,420.50 4,400,008,242.09 4,008,793,496.59 3,921,022,446.87